

Litifilimab Biosimilar - Research Grade

Product Code: ICH5648

More Information

Species Reactivity: Human

Target: CLEC4E^{1/2}

Concentration: 5mg/ml

Isotype: IgG1 - kappa

Host: CHO Cells

product name H2: Litifilimab Biosimilar - Research Grade

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: Q8WTT0

Shipping Conditions: Blue ice

background: CLEC4C (BDCA-2) is a C-type lectin restricted to plasmacytoid dendritic cells and a marker of interest in autoimmune and interferon biology research. This human IgG1, kappa antibody is an unconjugated, non-therapeutic analog of litifilimab that recognizes CLEC4C for functional studies. The preparation is low in endotoxin and therefore appropriate for in vivo experiments, and it is produced in scalable milligram-to-gram quantities to support high-throughput and bulk laboratories. Distributed for research use only (RUO), it functions as a binding control and active reagent in pDC-targeting assays, interferon-pathway readouts, in vitro screening, and preclinical models of lupus and related autoimmune disease.

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.



Purity: >90% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.